EGFR-TKI in non-small cell lung cancer treatment
10.3760/cma.j.issn.1673-422X.2012.08.012
- VernacularTitle:表皮生长因子受体酪氨酸激酶抑制剂与非小细胞肺癌的治疗
- Author:
Weihui ZHENG
;
Weimin MAO
- Publication Type:Journal Article
- Keywords:
Carcinoma,non-small-cell lung;
Receptor,epidermal growth factor;
Enzyme inhibitors
- From:
Journal of International Oncology
2012;39(8):601-604
- CountryChina
- Language:Chinese
-
Abstract:
The epidermal growth factor receptor tyrosine kinase inhibitor(EGFR-TKI)is a kind of high-efficiency and low-toxicity tumor molecular targeted drugs.It becomes a research hotspot in non-small cell lung cancer (NSCLC)treatment because of its unique curative effect and well tolerance.EGFR-TKI is mainly applied to the second and third line treatment of patients with advanced NSCLC or first line treatment of EGFR mutation patients.With the development of research,the indications of EGFR-TKI expand unceasingly.The preoperative neoadjuvant therapy is likely to become a new kind of treatment mode.
